{
  "id": 3238,
  "text": "Ann Oncol 9, 977-980 (1998).1176.Lacava, J.A., et al.Vinorelbine as neoadjuvant chemotherapy in advanced cervical carcinoma.J Clin Oncol 15, 604- 609 (1997).1177.Huang, H.J., et al.Prognostic value of age and histologic type in neoadjuvant chemotherapy plus radical surgery for bulky $( > / = 4$ cm) stage IB and IIA cervical carcinoma.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: Ann Oncol 9, 977-980 (1998).1176.Lacava, J.A., et al.Vinorelbine as neoadjuvant chemotherapy in advanced cervical carcinoma.J Clin Oncol 15, 604- 609 (1997).1177.Huang, H.J., et al.Prognostic value of age and histologic type in neoadjuvant chemotherapy plus radical surgery for bulky $( > / = 4$ cm) stage IB and IIA cervical carcinoma.\n\n<question>: \n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n",
  "ChatGPT_response_0": "根据研究和文献报道，对于体积较大的 (≥4 cm) IB 和 IIA 期宫颈癌患者，年龄和组织学类型对新辅助化疗加根治性手术的预后具有显著价值。年轻患者通常对治疗的耐受性更好，化疗后的肿瘤缩小率较高，从而提高了手术的完全切除率，改善了生存率。另一方面，肿瘤的组织学类型也在一定程度上影响治疗效果。例如，鳞状细胞癌一般对新辅助化疗的反应优于腺癌或其他稀有类型，这使得鳞状细胞癌患者在综合治疗后的预后更为乐观。\n\n因此，在治疗这些宫颈癌患者时，评估患者的年龄和肿瘤的组织学类型有助于制定个体化的治疗方案，以最大可能提高治疗疗效和长期结果。",
  "query": "根据提供的 <text>，内容与宫颈癌相关。\n\n<question>: 在治疗体积较大的 $( > / = 4$ cm) IB 和 IIA 期宫颈癌时，患者的年龄及组织学类型在新辅助化疗加根治性手术中的预后价值是什么？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 根据提供的 <text>，内容与宫颈癌相关。\n\n<question>: 在治疗体积较大的 $( > / = 4$ cm) IB 和 IIA 期宫颈癌时，患者的年龄及组织学类型在新辅助化疗加根治性手术中的预后价值是什么？\n\n<reference text>: Ann Oncol 9, 977-980 (1998).1176.Lacava, J.A., et al.Vinorelbine as neoadjuvant chemotherapy in advanced cervical carcinoma.J Clin Oncol 15, 604- 609 (1997).1177.Huang, H.J., et al.Prognostic value of age and histologic type in neoadjuvant chemotherapy plus radical surgery for bulky $( > / = 4$ cm) stage IB and IIA cervical carcinoma.\n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n\n<reply>: ",
  "response": "根据研究和文献报道，对于体积较大的 (≥4 cm) IB 和 IIA 期宫颈癌患者，年龄和组织学类型对新辅助化疗加根治性手术的预后具有显著价值。年轻患者通常对治疗的耐受性更好，化疗后的肿瘤缩小率较高，从而提高了手术的完全切除率，改善了生存率。另一方面，肿瘤的组织学类型也在一定程度上影响治疗效果。例如，鳞状细胞癌一般对新辅助化疗的反应优于腺癌或其他稀有类型，这使得鳞状细胞癌患者在综合治疗后的预后更为乐观。\n\n因此，在治疗这些宫颈癌患者时，评估患者的年龄和肿瘤的组织学类型有助于制定个体化的治疗方案，以最大可能提高治疗疗效和长期结果。"
}